Lemborexant

Evidence Level: N/A

Predicted Indications: 0

Lemborexant

Pharmacist Assessment Report

Lemborexant: Known uses and market status in India

Summary

The TxGNN deep-learning model (score ≥ 0.99) produced candidate indications for Lemborexant. Every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug.

Quick overview

Item	Content
New predicted indications	None (all traceable model candidates are known uses)
Known uses among model candidates	0
Evidence level	Not applicable
India Market Status	Listed in a compiled Indian medicine price dataset (2 of 2) – CDSCO approval status is not included in this data
Number of Listed Products	2 (valid: 2)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication	Source
none	none

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

India Market Information

Licence	Product	Dosage form	Status
61267	Dayvigo 5mg Tablet	strip of 14 tablets	Valid
61912	Dayvigo 10mg Tablet	strip of 14 tablets	Valid

Safety Considerations

Contraindication signals from the knowledge graph (not label text): narcolepsy, narcolepsy-cataplexy syndrome, central nervous system disease, Balo concentric sclerosis, X-linked adrenoleukodystrophy.
Drug Interactions: 160 interactions were identified. Major-level interactions include:
- Ranitidine
- Cimetidine
- Aprepitant
- Clarithromycin
- Clotrimazole
- Morphine (including liposomal morphine)
Moderate-level interactions include pioglitazone, bupropion, dexamethasone, saxagliptin, metoclopramide, dronabinol and nabilone, among others.

Please refer to the package insert for warnings and formal contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.